RECEIVED CENTRAL FAX CENTER

SEP 2 2 2005

Hadaaba Baasaada	7-4-5- A-1-4400C	U.S. P			through 07/31/2006. OMB 0851-0031 U.S. DEPARTMENT OF COMMERCE
CONTROL CADENACIA REGULARIO LASSA NO DESCON		Application Number	action of information unless Reference a valid OMB control number 10/761.982		displays a valid OMB control number.
TRANSMITTAL		Filing Date	January 21, 2004		
FORM		First Named Inventor	Michel TABART et al.		
		Art Unit	1626		
(to be used for all correspondence after initial filing)		Examiner Name	STOCKTON, Laura Lynne		ynne
Total Number of Pages In This Submission 18 pgs.		Attorney Docket Number	ST01021 US CNT		
ENCLOSURES (Check all that apply)					
Extension of Time Express Abandon Information Discle Certified Copy of I Document(s) Reply to Missing I Incomplete Applic	declaration(s) Request ment Request sure Statement Priority Remail	Drawing(6) Licensing-related Papers Petition Petition to Convert to a Provisional Application Power of Attornsy, Revocation Change of Correspondence A Terminal Disclaimer Request for Refund CD, Number of CD(s) Landscape Table on CD	ddress	Appead of Appead (Appead (Appe	
SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT					
Firm Name AVEN	AVENTIS PHARMACEUTICALS INC.				
Signature Balaram Gun					
Printed name Balaram GUPTA					
Date September 22, 2005 Reg. No. 40,009					
CERTIFICATE OF TRANSMISSION/MAILING I hereby certify that this correspondence is being facsimilis transmitted to the USPTO or deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on					
the date shown below: (USPTO FAX NO. 571-273-8900 ; Total No. of Pages Transmitted: 18 pgs.) Signature Moule Moule					
Typed or printed name	Maribel Mendez	8	_	Date	September 22, 2005

This collection of information is required by 97 CFR 1.5. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 57 CFR 1.11 end1.14. This collection is estimated to 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will very depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Dependment of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. OO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

SEP 2 2 2005

PATENT

Docket No.: ST01021 US CNT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of Michel Tabart et al.

Examiner:

Stockton, Laura

Muchel Tabart et al

Art Unit:

1626

Serial No.: 10/761,982

Filed:

January 21, 2004

TELEFAX CERTIFICATE

Title:

Indazole or indole derivatives, and use

thereof in human medicine and more

particularly in oncology

I hereby certify that this correspondence is being transmitted via factimile to the Commissioner for Patents, Alexandria, VA 22313, at (571) 273-8300 on

Mail Stop: Amendment. Commissioner for Patents P.O. Box 1450 Arlington, VA 22313-1450

Response to Notice of Non-Compliant Amendment (37 C.F.R. § 1,121)

Sir:

This Amendment in the above-identified patent application is in response to the Office Action, entitled "Notice of Non-Compliant Amendment (37 CFR 1.121)", dated, September 15, 2005, having a response due by October 15, 2005. Please find attached an amendment which now provides proper status identifier for all of the claims in the present case. More, specifically, the aforementioned notice indicated that claims 27-34 are withdrawn and should be identified as such. Further, it also noted that amended claims, such as, claims 27 and 31 should be identified as "Withdrawn-Currently amended." It is respectfully submitted that these identifiers have now been appropriately incorporated into the amendments attached herewith. Accordingly, it is submitted that this amendment fully satisfies the requirements of 37 CFR 1.121. Thus, it is respectfully requested that the following amendment be entered in this case.

ST01021 US CNT

-1 of 17-

Application Ser. No.: 10/761,982 Filing Date: January 21, 2004 Examiner: Stockton, Laura

Applicants believe there are no fees due for this Amendment. However, if the Examiner deems that fees are due, please charge these fees to Deposit Account No. 18-1982 for Aventis Pharmaceuticals Inc. Bridgewater, NJ. Please credit any overpayment to Deposit Account No. 18-1982.

Respectfully submitted,

Balaram Gupta

Registration No. 40,009 Attorney for Applicants

Aventis Pharmaceuticals Inc.
Patent Department
Route #202-206 / P.O. Box 6800

September 22, 2005

MAIL CODE: BWD-303A

Bridgewater, NJ 08807-0800 Telephone: 908-231-3364 Telefax: 908-231-2626